Innovations in cardiac device therapy in the era of advanced rhythm management: implantable defibrillators and conduction system pacing Authors: Margarida Pujol-Lopez, Roderick Tung, Lluis Mont Published: 2026 ABSTRACT AbstractCardiac device therapy has significantly evolved since the introduction of the first implantable pacemaker and the subsequent development of the implantable cardioverter-defibrillator (ICD). ICDs are highly effective; however, their main weakness lies in lead-related complications. To avoid the need for venous access and the complications associated with transvenous leads, a fully subcutaneous ICD (S-ICD) system was developed. Despite these advancements, the S-ICD system is limited by its inability to provide bradycardia pacing and antitachycardia pacing. This limitation prompted the development of a modular cardiac rhythm management system, integrating a new leadless pacemaker with an S-ICD that uses unidirectional communication to command the pacemaker to deliver antitachycardia pacing.Conduction system pacing, including His bundle pacing and left bundle branch area pacing (LBBAP), has emerged as a physiological alternative to biventricular resynchronisation therapy and conventional pacing, pending results of large clinical trials. LBBAP offers superior electrical parameters and long-term performance compared with His bundle pacing. The capability to provide defibrillation via the same lead used for LBBAP represents an unresolved challenge that is currently under ongoing research.This state-of-the-art review presents the latest developments and innovations in cardiac device therapy, offering a comprehensive overview of current technologies that increasingly enable therapy to be tailored to individual patient needs.Keywords: Tachycardia, Ventricular; Defibrillators, Implantable; Pacemaker, Artificial Introduction The complete implantation of a pacemaker in 1958 by the cardiac surgeon Åke Senning at the Karolinska Hospital—using a device designed by Rune Elmqvist with epicardial wires connected to a rechargeable generator placed in the abdominal wall—is considered the birth of modern pacemaker therapy.1 2 Michel Mirowski, with co-inventor Morton Mower, revolutionised the care of patients at risk of sudden death with the design of the implantable cardioverter-defibrillator (ICD).3 In 1980, the first human implant occurred4 and the device was approved by the US Food and Drug Administration in 1985.3 More than 65 years of evolution in cardiac device therapy have delivered unique contributions to improving patient outcomes, reducing procedural complications and advancing cardiac rhythm management (figure 1A). (A) Timeline of highlights in the evolution of cardiac devices3; (B) Diagrams of the new defibrillation systems. CRT-D, cardiac resynchronisation therapy-defibrillator; FDA, US Food and Drug Administration; ICD, implantable cardioverter-defibrillator. Highly sophisticated pacemaker and defibrillator devices are now in widespread use, thanks to numerous clinical scientists and engineers who have introduced technological advances to improve patient outcomes. Given the complications associated with transvenous ICDs, both short-term and long-term, the subcutaneous ICD (S-ICD) was developed in 2010.5 To overcome the absence of pacing capabilities in the S-ICD, a system comprising a leadless pacemaker (LP) in wireless communication with an S-ICD was developed6 (figure 1B). In the field of cardiac pacing, the major factors motivating the search for alternatives to conventional pacing are, on one hand, that right ventricular (RV) pacing causes dyssynchrony7 and pacing-induced cardiomyopathy;8 9 and on the other hand, that the ventricular activation pattern during biventricular pacing (BiVP)—characterised by slow cell-to-cell conduction from epicardium to endocardium—is non-physiological,10 and the non-responder rate persists at approximately 30%.11 Moreover, BiVP provides an activation characterised by epicardial onset in the left ventricle (LV), with two main foci of activation, LV and RV. Given this scenario, conduction system pacing (CSP) was developed to offer a more physiological and homogeneous activation. This manuscript provides a comprehensive overview of the latest innovations in cardiac device therapy, including the S-ICD, modular communicative leadless pacing–defibrillator system, extravascular ICD (EV-ICD) and CSP. Subcutaneous implantable cardioverter-defibrillator Clinical rationale Since the first transvenous ICD implants,4 robust evidence from high-quality randomised controlled trials has supported their use across various patient populations, including cardiac arrest survivors, patients with ventricular tachycardia (VT) and structural heart disease, and those with significant LV dysfunction.12 Transvenous ICDs are associated with a significant number of complications, of which many are related to the lead; the transvenous lead is the Achilles heel of these devices.13 The risk of complications is present both during the implantation procedure (pneumothorax/haemothorax, lead dislodgement, cardiac perforation/pericardial tamponade) and during long-term follow-up (lead malfunction, endovascular infection, venous thrombosis/occlusion).3 Results from a large healthcare database14 showed that 5.3% of the study cohort had a mechanical complication from the ICD lead, whereas 1.9% had an infectious complication involving the ICD lead over a mean follow-up of 2.3 years. The risk of mechanical failure of transvenous ICD leads was 25% at 10 years.14 Moreover, if transvenous lead extraction is required, there is a risk of major complications, urgent cardiac surgery and a 0.9% risk of in-hospital deaths during lead extraction procedures.15 To eliminate the need for venous access, an entirely subcutaneous system was introduced in 2010.5 Fundamentals The S-ICD consists of a subcutaneous pulse generator implanted in the midaxillary position on the left side of the thoracic wall, and a parasternal subcutaneous lead with an 8 cm coil16 (figure 1B). The current third-generation device is magnetic resonance compatible, has an atrial fibrillation monitor and incorporates a novel algorithm aimed at minimising inappropriate therapy (SMART Pass (Boston Scientific, Marlborough, Massachusetts, USA)).16 Efficacy and safety In patients with an indication for an ICD but no indication for pacing, the PRAETORIAN trial17 showed that the S-ICD was non-inferior to the transvenous ICD with respect to device-related complications and inappropriate shocks. The UNTOUCHED study18 was a non-randomised study that enrolled primary prevention patients with left ventricular ejection fraction (LVEF) ≤35% and no pacing indication; it showed freedom from inappropriate shocks at 17-month follow-up of 95.9%, and a conversion success rate for appropriate episodes of 98.4%. The ATLAS trial19 found a significant reduction in perioperative lead-related complications, which occurred in 0.4% of S-ICD and 4.8% of transvenous ICD implants. The S-ICD postapproval study20 real-world multicentre registry, with a 4.2-year median follow-up, showed 98.4% shock efficacy for VT or ventricular fibrillation; S-ICD-related and electrode-related complication-free rates were 93.4% and 99.3%, respectively. The recently published PRAETORIAN-XL21 trial demonstrated no significant difference between the S-ICD and transvenous ICD in all device-related complications during long-term follow-up (median follow-up 87.5 months). (online supplemental material table 1). heartjnl-112-17-s001.pdf Target population The S-ICD may be preferred in patients with limited vascular access, previous device infections or high infection risk12 such as dialysis, immunodeficiency and prosthetic heart valves. The S-ICD is also a viable alternative for patients with hypertrophic cardiomyopathy,19 arrhythmogenic RV cardiomyopathy22 and Brugada syndrome.16 23 (table 1A summarises international recommendations on ICD indications). Table 1International recommendations on ICD (A) and CSP (B)(A) Recommendations according to ICD typeTransvenous ICDSubcutaneous ICDExtravascular ICDModular systemWearable cardioverter-defibrillator2022 ESC Guidelines22 2017 AHA/ACC/HRS Guideline12 2022 ESC Guidelines22 2017 AHA/ACC/HRS Guideline12 Not included in current guidelinesNot included in current guidelines 2022 ESC Guidelines 22 2017 AHA/ACC/HRS Guideline12 ICD indications for ventricular arrhythmias (primary and secondary prevention), ischaemic and non-ischaemic cardiomyopathies, Brugada syndrome, channelopathies and genetic heart diseases. Should be considered as an alternative to transvenous ICD when ICD is indicated but pacing therapy for bradycardia, cardiac resynchronisation or ATP is not needed.22 Recommended in patients who meet criteria for an ICD but have inadequate vascular access or are at high risk for infection, and in whom pacing for bradycardia or VT termination or as part of CRT is neither needed nor anticipated.12 Reasonable when ICD is indicated and pacing for bradycardia or VT termination or as part of CRT is neither needed nor anticipated.12 Should be considered for adult patients with a secondary prevention ICD indication, who are temporarily not candidates for ICD implantation.22 May be considered in the early phase after myocardial infarction in selected patients.22 May be reasonable in patients at increased risk of sudden cardiac death who are not ineligible for an ICD, such as awaiting cardiac transplant, LVEF ≤35% and within 40 days post myocardial infarction, or with newly diagnosed non-ischaemic cardiomyopathy, revascularisation within the past 90 days, myocarditis or secondary cardiomyopathy or a systemic infection.12 (B) Recommendations for CSP: HBP or LBBAP2018 ACC/AHA/HRS Guideline75 ESC 2019 Guidelines83 ESC 2021 Guidelines76 2023 HRS/APHRS/LAHRS Guideline77 ESC Consensus 202555 In patients with AV block who have an indication for permanent pacing with LVEF 36%–50% and are expected to require ventricular pacing >40%, it is reasonable to choose BiVP or HBP.In patients with AV block who have an indication for permanent pacing, HBP may be considered to maintain physiological activation. AV nodal ablation with subsequent BiVP or HBP (ablate and pace strategy) should be considered if the supraventricular tachycardia cannot be ablated. In CRT candidates in whom coronary sinus lead implantation is unsuccessful, HBP should be considered.In patients treated with HBP, implantation of a right ventricular lead as ‘backup’ should be considered.HBP with a ventricular backup lead may be considered in patients in whom an ablate and pace strategy is indicated, particularly when intrinsic QRS is narrow.HBP may be considered as an alternative to right ventricular pacing in patients with AV block and LVEF>40% who are anticipated to require >20% ventricular pacing. Recommendations are included for the following:Patients with indications for pacemaker aiming to reduce the risk of pacing-induced cardiomyopathy.Patients without indications for a pacemaker who have heart failure (CRT indication).Patients with atrial fibrillation requiring cardiac physiological pacing (ablate and pace strategy). Advice is included for LBBAP and HBP (see details in table 3) in the context of the following:AV block.CRT.AV node ablation.LOT/HOT-CRT (combination of HBP or LBBAP with a lead in the coronary sinus). The wearable cardioverter-defibrillator is a non-implantable external defibrillator that has been shown to successfully detect and treat VT and ventricular fibrillation; it has been included to provide a broader perspective on all available defibrillator options. The American College of Cardiology, the Heart Rhythm Society, together with other US professional societies, issued the 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators84 ACC, American College of Cardiology; AHA, American Heart Association; APHRS, Asia Pacific Heart Rhythm Society; ATP, antitachycardia pacing; AV, atrioventricular; BiVP, biventricular pacing; CRT, cardiac resynchronisation therapy; CSP, conduction system pacing; ESC, European Society of Cardiology; HBP, His bundle pacing; HRS, Heart Rhythm Society; ICD, implantable cardioverter-defibrillator; LAHRS, Latin American Heart Rhythm Society; LBBAP, left bundle branch area pacing; LVEF, left ventricular ejection fraction; VT, ventricular tachycardia. International recommendations on ICD (A) and CSP (B) ICD indications for ventricular arrhythmias (primary and secondary prevention), ischaemic and non-ischaemic cardiomyopathies, Brugada syndrome, channelopathies and genetic heart diseases. ICD indications for ventricular arrhythmias (primary and secondary prevention), ischaemic and non-ischaemic cardiomyopathies, Brugada syndrome, channelopathies and genetic heart diseases. Should be considered as an alternative to transvenous ICD when ICD is indicated but pacing therapy for bradycardia, cardiac resynchronisation or ATP is not needed.22 Should be considered as an alternative to transvenous ICD when ICD is indicated but pacing therapy for bradycardia, cardiac resynchronisation or ATP is not needed.22 Recommended in patients who meet criteria for an ICD but have inadequate vascular access or are at high risk for infection, and in whom pacing for bradycardia or VT termination or as part of CRT is neither needed nor anticipated.12 Recommended in patients who meet criteria for an ICD but have inadequate vascular access or are at high risk for infection, and in whom pacing for bradycardia or VT termination or as part of CRT is neither needed nor anticipated.12 Reasonable when ICD is indicated and pacing for bradycardia or VT termination or as part of CRT is neither needed nor anticipated.12 Reasonable when ICD is indicated and pacing for bradycardia or VT termination or as part of CRT is neither needed nor anticipated.12 Should be considered for adult patients with a secondary prevention ICD indication, who are temporarily not candidates for ICD implantation.22 Should be considered for adult patients with a secondary prevention ICD indication, who are temporarily not candidates for ICD implantation.22 May be considered in the early phase after myocardial infarction in selected patients.22 May be considered in the early phase after myocardial infarction in selected patients.22 May be reasonable in patients at increased risk of sudden cardiac death who are not ineligible for an ICD, such as awaiting cardiac transplant, LVEF ≤35% and within 40 days post myocardial infarction, or with newly diagnosed non-ischaemic cardiomyopathy, revascularisation within the past 90 days, myocarditis or secondary cardiomyopathy or a systemic infection.12 May be reasonable in patients at increased risk of sudden cardiac death who are not ineligible for an ICD, such as awaiting cardiac transplant, LVEF ≤35% and within 40 days post myocardial infarction, or with newly diagnosed non-ischaemic cardiomyopathy, revascularisation within the past 90 days, myocarditis or secondary cardiomyopathy or a systemic infection.12 In patients with AV block who have an indication for permanent pacing with LVEF 36%–50% and are expected to require ventricular pacing >40%, it is reasonable to choose BiVP or HBP. In patients with AV block who have an indication for permanent pacing with LVEF 36%–50% and are expected to require ventricular pacing >40%, it is reasonable to choose BiVP or HBP. In patients with AV block who have an indication for permanent pacing, HBP may be considered to maintain physiological activation. In patients with AV block who have an indication for permanent pacing, HBP may be considered to maintain physiological activation. AV nodal ablation with subsequent BiVP or HBP (ablate and pace strategy) should be considered if the supraventricular tachycardia cannot be ablated. AV nodal ablation with subsequent BiVP or HBP (ablate and pace strategy) should be considered if the supraventricular tachycardia cannot be ablated. In CRT candidates in whom coronary sinus lead implantation is unsuccessful, HBP should be considered. In CRT candidates in whom coronary sinus lead implantation is unsuccessful, HBP should be considered. In patients treated with HBP, implantation of a right ventricular lead as ‘backup’ should be considered. In patients treated with HBP, implantation of a right ventricular lead as ‘backup’ should be considered. HBP with a ventricular backup lead may be considered in patients in whom an ablate and pace strategy is indicated, particularly when intrinsic QRS is narrow. HBP with a ventricular backup lead may be considered in patients in whom an ablate and pace strategy is indicated, particularly when intrinsic QRS is narrow. HBP may be considered as an alternative to right ventricular pacing in patients with AV block and LVEF>40% who are anticipated to require >20% ventricular pacing. HBP may be considered as an alternative to right ventricular pacing in patients with AV block and LVEF>40% who are anticipated to require >20% ventricular pacing. Patients with indications for pacemaker aiming to reduce the risk of pacing-induced cardiomyopathy. Patients with indications for pacemaker aiming to reduce the risk of pacing-induced cardiomyopathy. Patients without indications for a pacemaker who have heart failure (CRT indication). Patients without indications for a pacemaker who have heart failure (CRT indication). Patients with atrial fibrillation requiring cardiac physiological pacing (ablate and pace strategy). Patients with atrial fibrillation requiring cardiac physiological pacing (ablate and pace strategy). AV block. AV block. CRT. CRT. AV node ablation. AV node ablation. LOT/HOT-CRT (combination of HBP or LBBAP with a lead in the coronary sinus). LOT/HOT-CRT (combination of HBP or LBBAP with a lead in the coronary sinus). The wearable cardioverter-defibrillator is a non-implantable external defibrillator that has been shown to successfully detect and treat VT and ventricular fibrillation; it has been included to provide a broader perspective on all available defibrillator options. The American College of Cardiology, the Heart Rhythm Society, together with other US professional societies, issued the 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators84 ACC, American College of Cardiology; AHA, American Heart Association; APHRS, Asia Pacific Heart Rhythm Society; ATP, antitachycardia pacing; AV, atrioventricular; BiVP, biventricular pacing; CRT, cardiac resynchronisation therapy; CSP, conduction system pacing; ESC, European Society of Cardiology; HBP, His bundle pacing; HRS, Heart Rhythm Society; ICD, implantable cardioverter-defibrillator; LAHRS, Latin American Heart Rhythm Society; LBBAP, left bundle branch area pacing; LVEF, left ventricular ejection fraction; VT, ventricular tachycardia. Modular pacing–defibrillator system Clinical rationale Defibrillator shocks are associated with a higher risk of death, and the number of shocks contributes to this risk, whereas antitachycardia pacing (ATP) does not appear to increase mortality risk.24 25 ATP has been shown to reduce the number of unnecessary and inappropriate shocks and improve patient quality of life and device longevity.26–28 Since the S-ICD cannot deliver ATP, it is contraindicated in patients who present with recurrent sustained monomorphic VT treatable with ATP.12 22 The recently published APPRAISE ATP trial29 demonstrated that a single burst of ATP prior to shock delivery reduced the relative risk of time to first all-cause shock by 28% in patients with primary prevention ICD. However, the reduction in first all-cause ICD shock did not extend to a reduction in all-cause shock burden or mortality. The benefit of ATP may be limited and might be reserved for patients who experience VT. This would justify S-ICD implantation and adding an LP only if ATP or bradycardia pacing is required (modular pacing–defibrillator system). Fundamentals After preclinical studies in animal models,30 31 a modular pacing–defibrillator system was designed to deliver ATP without the risks associated with transvenous leads. This modular cardiac rhythm management (mCRM) system consists of an LP in wireless communication with an S-ICD (Boston Scientific) (figure 1B). The LP is a rate-responsive, single-chamber RV pacemaker (32 mm long and 6 mm in diameter) with active fixation to the endocardium via active-fixation nitinol tines.32 The LP is implanted under fluoroscopy through a 21F inner diameter introducer sheath and can be retrieved by a dedicated retrieval catheter.32 The pacing–defibrillator system relies on unidirectional communication from the S-ICD to the LP for ATP delivery.6 When device therapy is warranted to treat a ventricular arrhythmia, the S-ICD has one-way communication capabilities to transmit an ATP request signal to the LP. The modality used for interdevice communication is galvanic coupling or conducted communication.33 34 Through galvanic coupling, one implanted device transmits low-energy electrical signals, which are detected by the receiving device.35 The technology was developed for both de novo implants and patients with an existing S-ICD, eliminating the need to explant and replace the pulse generator. To use pre-existing hardware, the existing circuitry within the S-ICD pulse generator (originally designed to assess shock circuit integrity) was repurposed to deliver bursts of approximately 25 kHz pulses from the electrode’s shock coil to the S-ICD pulse generator can.35 These pulses are sent in a proprietary pattern that can be recognised by the LP.35 The S-ICD messages are sent coincident with the sensed R-wave to avoid oversensing and provide built-in redundancy to avoid the risk of failed communication. ATP can be programmed with the external programmer. The S-ICD continuously monitors the ATP therapy results. If the ATP successfully terminates the tachycardia and returns the heart to a normal rhythm, the S-ICD will continue monitoring, and no shock will be delivered. If VT persists, the S-ICD will deliver shock therapy. Efficacy and safety The MODULAR ATP trial tested the safety and efficacy of the mCRM system in a multinational, single-group study that included 282 patients.6 32 In that trial, LP in wireless communication with S-ICD exceeded prespecified performance goals for freedom from major LP-related complications (97.5%), successful communication between the LP and the S-ICD (98.8%) and percentage of patients with a pacing threshold of up to 2 V at 0.4 ms at 6 months (97.4%)6 (figure 2) (online supplemental material table 1). Modular communicative leadless pacing–defibrillator system. A 50-year-old patient with a history of hypertrophic cardiomyopathy (dilated phase), presenting with LVEF of 35%, extensive patchy septal fibrosis on cardiac MRI and narrow QRS. Ambulatory ECG monitoring revealed runs of non-sustained VT lasting up to 37 beats. Patient was considered to be at high risk for monomorphic VT, and implantation of a modular communicative leadless pacing–defibrillator system was indicated for primary prevention of sudden cardiac death (patient included in the MODULAR-ATP trial6 at Hospital Clinic Barcelona). An X-ray of the patient with the implanted device is shown in the figure. The S-ICD uses unidirectional conductive communication to command the leadless pacemaker to deliver ATP. The communication (pulses: 0.5–4 V amplitude, 25 kHz) is coupled to the sensed R-wave and transmitted redundantly (two identical messages are sent to reduce the risk of communication failure).35 Main results of the MODULAR-ATP trial are shown at the bottom of the figure. ATP, antitachycardia pacing; LVEF, left ventricular ejection fraction; S-ICD, subcutaneous implantable cardioverter-defibrillator; VT, ventricular tachycardia. The ATP successfully terminated 61% of arrhythmia episodes; there were no episodes for which ATP was not delivered owing to communication failure.6 Ventricular perforation occurred in 1.2% of the patients, a percentage similar to that reported with the implantation of other single-chamber LPs.36 Target population There is currently insufficient evidence to formulate guideline recommendations. Larger studies in diverse patient populations are needed. The MODULAR ATP trial6 excluded patients indicated for dual-chamber pacing or cardiac resynchronisation therapy (CRT), those with other implanted devices that could interfere with the LP system, patients requiring rate-responsive pacing and individuals who were entirely pacemaker-dependent. Extravascular implantable cardioverter-defibrillator Clinical rationale The EV-ICD system (Aurora EV-ICD, Medtronic, Minneapolis, USA) is another technological innovation designed to provide the benefits of an EV-ICD while delivering pause-prevention pacing and ATP. The S-ICD lead requires a high current for pacing and defibrillation because of its extracardiac location, necessitating a larger device.37 The EV-ICD uses a novel substernal lead placement to address these limitations.38 Fundamentals The EV-ICD pulse generator is implanted along the patient’s left midaxillary line. The lead is positioned substernally using a tunnelling tool, with placement guided by fluoroscopy. The lead has an epsilon shape with two pace/sense electrodes and two defibrillation coil segments (4 cm each) that are tied together for defibrillation purposes to form an overall 8 cm defibrillation coil.38 Efficacy and safety The EV-ICD pivotal study, a prospective, multicentre, single-group, non-randomised study,37 showed that the EV-ICD could be implanted safely and that it effectively terminated acute ventricular arrhythmias, exceeding the prespecified efficacy and safety criteria. The primary efficacy endpoint—successful defibrillation at implantation—was achieved in 98.7% of patients, while 92.6% of patients remained free from major system or procedure-related complications at 6 months.37 At a mean follow-up of 30.6 months,39 the EV-ICD system terminated spontaneous ventricular arrhythmias with a high rate of ATP and defibrillation therapy success (77% and 100%, respectively) and a low major complication rate. The Enlighten study40 is a prospective, postmarket registry study designed to assess the performance of the EV-ICD system in real-world clinical practice and its safety at 5-year follow-up. Preliminary results40 show a high success rate for terminating induced ventricular arrhythmia episodes at implant and a low rate of periprocedural major complications at discharge, comparable with the premarket experience (online supplemental material table 1). Target population There is currently insufficient evidence to formulate guideline recommendations for the EV-ICD. This device is not indicated in patients who require bradycardia pacing or CRT, as well as in those with a history of prior sternotomy.39 Knowledge gaps in modern defibrillator therapy It is important to emphasise that, although new technologies have generated considerable enthusiasm, a cautious approach is warranted, as the available evidence is substantially more limited compared with endovascular ICDs and long-term follow-up data remain scarce. For EV-ICD studies, defibrillation testing may not accurately reflect the clinical shock efficacy, and the authors of the articles cited acknowledge that the study population was younger than typical ICD recipients.37 39 40 Currently, no randomised or long-term evidence is available for the EV-ICD or for the modular pacing–defibrillator system; therefore, guidelines have not yet defined the specific patient population for which these technologies are indicated. In contrast, the evidence regarding S-ICDs is extensive (online supplemental material table 1). The safety and efficacy of the S-ICD are non-inferior to transvenous devices, with low rates of inappropriate shocks and complications.17–20 Furthermore, these benefits are maintained over long-term follow-up,21 41 supporting the S-ICD as a reliable and effective alternative to traditional transvenous defibrillators. However, gaps remain in long-term follow-up data, partly because the studies and informed consent were not originally designed for extended observation and also due to the low inclusion of women, constituting less than 20% of participants in the PRAETORIAN-XL trial21 and 28% in the EFFORTLESS study.41 Conduction system pacing A more physiological alternative to biventricular and RV pacing has been sought for years. Although BiVP partially corrects dyssynchronous contraction,42 it yields significantly longer activation times compared with the intact conduction system, and 30% of patients are clinical non-responders. Regarding RV pacing, it could be harmful in a considerable number of patients: the incidence of pacing-induced cardiomyopathy is estimated to be around 9% at 12-month follow-up43 and 19%–23% with longer follow-up.44 45 In this scenario, His bundle pacing (HBP) and left bundle branch area pacing (LBBAP) have arisen as a possible new resynchronisation therapy or pacing modality. His bundle pacing HBP is considered the most physiological pacing method, as it engages the native conduction system, resulting in simultaneous activation of both ventricles. Using computational modelling, Meiburg et al 46 showed that HBP was theoretically the superior CSP mode, leading to the most synchronous electrical activation and homogeneous distribution of mechanical work. In 1967, Scherlag et al 47 described successful acute His bundle stimulation in a canine model, with preserved normal sequential ventricular activation. In 1977, Narula48 reported that HBP distal to the lesion normalised the QRS in patients with left bundle branch block (LBBB) due to synchronous impulse conduction through both bundle branches, right and left. However, it was not until 2000 that Deshmukh et al 49 published the first series on permanent HBP, demonstrating that HBP is a feasible approach in patients with chronic atrial fibrillation and dilated cardiomyopathy, leading to reduced LV dimensions and improved cardiac function. In 2005, Moriña et al described for the first time that HBP may be a possible alternative to BiVP in cases of difficult coronary sinus access.50 Since then, several observational studies51 and a few randomised clinical trials52–54 (table 2, figure 3A) have been published with encouraging preliminary results. However, technical difficulties in achieving the target pacing site, unsatisfactory electrical lead parameters (eg, increase in pacing thresholds over time) and the inability to correct infra-Hisian or more distal conduction disease limit the adoption of HBP as a standard alternative to BiVP.55 The His-SYNC53 trial showed a 48% crossover from HBP to BiVP; one-half of patients exhibited intraventricular conduction delay (intact Purkinje activation), which is unlikely to be corrected by HBP.56 Table 2Conduction system pacing randomised clinical trials for CRT indicationTrial; year of publicationNInterventionKey inclusion criteriaOnly LBBBCross-over(from CSP to BiVP)Primary outcomeMajor findings regarding the primary endpointLustgarten et al; 201552 29All patients BiVP+HBP.Crossover trial (6 months at each setting).CRT indication with QRS duration >130 ms.Exclusion criteria: atrial fibrillation, complete infra-Hisian block.NoBoth electrodes were implanted by design.(8/29 lacked QRS narrowing+2/29 threshold too high) Feasibility of, and clinical response to, permanent HBP. Feasibility of normalising the QRS in patients with bundle branch block disease using HBP.HBP can elicit a 6-month CRT response comparable to that of BiVP. His-SYNC;201953 NCT0270042541HBP versus BiVPPatients meeting guideline indications for CRT.No48% Change in QRS duration.Improvement in LVEF at 6 months.Cardiovascular hospitalisation or death at 12 months. A significant reduction in QRS duration was observed with HBP but not with BiVP.HBP was not superior to BiVP with regard to LVEF improvement.No differences were observed in cardiovascular hospitalisation or death at 12 months between groups. His-Alternative; 202154 NCT0361416950HBP versus BiVPHeart failure with LVEF ≤35%, NYHA class II–IV despite optimisation of medical therapy and sinus rhythm with LBBB.Yes28% Success rate of implanting a pacing lead to the His-bundle with capture of the left bundle and maintaining this effect for 6 months. Successful HBP implantation with capture of the left bundle sustained through 6-month follow-up was achieved in 72% of patients assigned to HBP. LEVEL-AT; 202264 NCT0405489570CSP versus BiVP(4/35 HBP, 31/35 LBBP) Heart failure; optimal medical treatment; LVEF≤35% and wide QRS (LBBB with QRS ≥130 or QRS≥150 ms in non-LBBB).AV block and LVEF <40%. No23% Left ventricular activation time measured with ECG imaging at 45-day follow-up. Non-inferiority of CSP compared with BiVP regarding the degree of cardiac resynchronisation (left ventricular activation time). LBBP-Resync; 202265 NCT0411043140LBBP versus BiVP Non-ischaemic cardiomyopathy, sinus rhythm, LBBB, LVEF ≤40% and NYHA class II–IV.At least 3 months of guideline-directed medical therapy. Yes10% Difference in LVEF improvement between the two groups at 6-month follow-up. LBBP demonstrated greater LVEF improvement than BiVP in heart failure patients with non-ischaemic cardiomyopathy and LBBB. HOT-CRT; 202366 NCT04561778100CSP versus BiVP.*If CSP resulted in incomplete electrical resynchronisation, a coronary sinus lead was added. Heart failure with ischaemic or non-ischaemic cardiomyopathy, and at least one of the following: LV systolic dysfunction with LVEF ≤35% and LBBB with QRS duration >120 ms; non-LBBB with QRS duration >150 ms or LVEF ≤50% and with (or need for) >40% RV pacing. No14%(cross-over or need for LBBP+coronary sinus lead) Change in LVEF at 6 months.Primary safety endpoint: freedom from major complications. CSP was associated with greater improvement in LVEF compared with BiVP.The primary safety endpoint of freedom from major complications (cardiac tamponade, late perforation of the lead into the LV, transient ischaemic attack or cerebrovascular accident, infection requiring explantation or CRT lead revision) was similar in both groups (no differences). CONSYST-CRT; 202568*NCT05187611134CSP versus BiVP(4/67 HBP; 63/67 LBBP) Heart failure; optimal medical treatment; LVEF ≤35% and wide QRS (LBBB with QRS ≥130 or QRS ≥150 ms in non-LBBB).AV block and LVEF <40%. No26.9% Combined endpoint was all-cause mortality, cardiac transplant, heart failure hospitalisation or LVEF improvement <5 points at 12 months. CSP was non-inferior to BiVP in achieving the clinical combined endpoint. CSP-SYNC;202585 NCT0515586562LBBAP versus BiVP Symptomatic heart failure despite optimal medical therapy, sinus rhythm, LVEF ≤35%, QRS duration ≥150 ms and LBBB. Yes3% Change in LVEF at 6 months LBBAP was non-inferior to BiVP in improving LVEF.*Inclusion and exclusion criteria were the same as in the LEVEL-AT trial from which the first 70 patients for the present study were recruited (prespecified in the protocol and ClinicalTrials.gov).AV, atrioventricular; BiVP, biventricular pacing; CRT, cardiac resynchronisation therapy; CSP, conduction system pacing; HBP, His bundle pacing; LBBAP, left bundle branch area pacing; LBBB, left bundle branch block; LBBP, left bundle branch pacing; LV, left ventricle; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RV, right ventricle. Conduction system pacing randomised clinical trials for CRT indication Feasibility of, and clinical response to, permanent HBP. Feasibility of, and clinical response to, permanent HBP. Feasibility of normalising the QRS in patients with bundle branch block disease using HBP. Feasibility of normalising the QRS in patients with bundle branch block disease using HBP. HBP can elicit a 6-month CRT response comparable to that of BiVP. HBP can elicit a 6-month CRT response comparable to that of BiVP. Change in QRS duration. Change in QRS duration. Improvement in LVEF at 6 months. Improvement in LVEF at 6 months. Cardiovascular hospitalisation or death at 12 months. Cardiovascular hospitalisation or death at 12 months. A significant reduction in QRS duration was observed with HBP but not with BiVP. A significant reduction in QRS duration was observed with HBP but not with BiVP. HBP was not superior to BiVP with regard to LVEF improvement. HBP was not superior to BiVP with regard to LVEF improvement. No differences were observed in cardiovascular hospitalisation or death at 12 months between groups. No differences were observed in cardiovascular hospitalisation or death at 12 months between groups. Success rate of implanting a pacing lead to the His-bundle with capture of the left bundle and maintaining this effect for 6 months. Success rate of implanting a pacing lead to the His-bundle with capture of the left bundle and maintaining this effect for 6 months. Successful HBP implantation with capture of the left bundle sustained through 6-month follow-up was achieved in 72% of patients assigned to HBP. Successful HBP implantation with capture of the left bundle sustained through 6-month follow-up was achieved in 72% of patients assigned to HBP. Heart failure; optimal medical treatment; LVEF≤35% and wide QRS (LBBB with QRS ≥130 or QRS≥150 ms in non-LBBB). Heart failure; optimal medical treatment; LVEF≤35% and wide QRS (LBBB with QRS ≥130 or QRS≥150 ms in non-LBBB). AV block and LVEF <40%. AV block and LVEF <40%. Left ventricular activation time measured with ECG imaging at 45-day follow-up. Left ventricular activation time measured with ECG imaging at 45-day follow-up. Non-inferiority of CSP compared with BiVP regarding the degree of cardiac resynchronisation (left ventricular activation time). Non-inferiority of CSP compared with BiVP regarding the degree of cardiac resynchronisation (left ventricular activation time). Non-ischaemic cardiomyopathy, sinus rhythm, LBBB, LVEF ≤40% and NYHA class II–IV. Non-ischaemic cardiomyopathy, sinus rhythm, LBBB, LVEF ≤40% and NYHA class II–IV. At least 3 months of guideline-directed medical therapy. At least 3 months of guideline-directed medical therapy. Difference in LVEF improvement between the two groups at 6-month follow-up. Difference in LVEF improvement between the two groups at 6-month follow-up. LBBP demonstrated greater LVEF improvement than BiVP in heart failure patients with non-ischaemic cardiomyopathy and LBBB. LBBP demonstrated greater LVEF improvement than BiVP in heart failure patients with non-ischaemic cardiomyopathy and LBBB. Heart failure with ischaemic or non-ischaemic cardiomyopathy, and at least one of the following: LV systolic dysfunction with LVEF ≤35% and LBBB with QRS duration >120 ms; non-LBBB with QRS duration >150 ms or LVEF ≤50% and with (or need for) >40% RV pacing. Heart failure with ischaemic or non-ischaemic cardiomyopathy, and at least one of the following: LV systolic dysfunction with LVEF ≤35% and LBBB with QRS duration >120 ms; non-LBBB with QRS duration >150 ms or LVEF ≤50% and with (or need for) >40% RV pacing. Change in LVEF at 6 months. Change in LVEF at 6 months. Primary safety endpoint: freedom from major complications. Primary safety endpoint: freedom from major complications. CSP was associated with greater improvement in LVEF compared with BiVP. CSP was associated with greater improvement in LVEF compared with BiVP. The primary safety endpoint of freedom from major complications (cardiac tamponade, late perforation of the lead into the LV, transient ischaemic attack or cerebrovascular accident, infection requiring explantation or CRT lead revision) was similar in both groups (no differences). The primary safety endpoint of freedom from major complications (cardiac tamponade, late perforation of the lead into the LV, transient ischaemic attack or cerebrovascular accident, infection requiring explantation or CRT lead revision) was similar in both groups (no differences). Heart failure; optimal medical treatment; LVEF ≤35% and wide QRS (LBBB with QRS ≥130 or QRS ≥150 ms in non-LBBB). Heart failure; optimal medical treatment; LVEF ≤35% and wide QRS (LBBB with QRS ≥130 or QRS ≥150 ms in non-LBBB). AV block and LVEF <40%. AV block and LVEF <40%. Combined endpoint was all-cause mortality, cardiac transplant, heart failure hospitalisation or LVEF improvement <5 points at 12 months. Combined endpoint was all-cause mortality, cardiac transplant, heart failure hospitalisation or LVEF improvement <5 points at 12 months. CSP was non-inferior to BiVP in achieving the clinical combined endpoint. CSP was non-inferior to BiVP in achieving the clinical combined endpoint. Symptomatic heart failure despite optimal medical therapy, sinus rhythm, LVEF ≤35%, QRS duration ≥150 ms and LBBB. Symptomatic heart failure despite optimal medical therapy, sinus rhythm, LVEF ≤35%, QRS duration ≥150 ms and LBBB. Change in LVEF at 6 months Change in LVEF at 6 months *Inclusion and exclusion criteria were the same as in the LEVEL-AT trial from which the first 70 patients for the present study were recruited (prespecified in the protocol and ClinicalTrials.gov). AV, atrioventricular; BiVP, biventricular pacing; CRT, cardiac resynchronisation therapy; CSP, conduction system pacing; HBP, His bundle pacing; LBBAP, left bundle branch area pacing; LBBB, left bundle branch block; LBBP, left bundle branch pacing; LV, left ventricle; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RV, right ventricle. CRT in 2025. (A) Advantages and disadvantages of CSP and BiVP, as well as an evidence pyramid with the randomised studies currently available and published. (B) CSP with LBBP is a more physiological pacing modality than BiVP; it uses the heart’s intrinsic conduction system and avoids the slow cell-to-cell activation caused by epicardial stimulation (left ventricular pacing through the coronary sinus). BiVP provides an activation characterised by epicardial onset in the lateral left ventricle, with two main foci of activation, left ventricle (in red) and right ventricle. We can see that both techniques correct the baseline dyssynchrony caused by LBBB or RV pacing. LBBP provides a more physiological and homogeneous activation than BiVP. BiVP, biventricular pacing; CRT, cardiac resynchronisation therapy; CSP, conduction system pacing; IVCD, intraventricular conduction delay; LBBB, left bundle branch block; LBBP, left bundle branch pacing; RV, right ventricular. The ALTERNATIVE-AF57 crossover trial included 50 patients with persistent atrial fibrillation and LVEF ≤40%; all patients underwent atrioventricular (AV) node ablation and received both HBP and BiVP. Patients were randomised to either HBP or BiVP for 9 months, then were switched to the alternative pacing modality for the next 9 months. HBP delivered a modest but significant improvement in LVEF compared with BiVP in patients with AV node ablation. In a registry of 2342 patients, the lead complication rate for HBP and LBBAP was 6.3% and 2.5%, respectively, at 36-month follow-up.58 Kron et al 59 reported that LBBAP pacing could offer the best of HBP (safe and effective physiological pacing) with the long-term durability of traditional RV pacing leads. The more favourable electrical parameters and fewer lead-related complications that have been reported led to the general adoption of LBBAP over HBP.58 Left bundle branch area pacing LBBAP includes left bundle branch pacing (LBBP), left fascicular and LV septal pacing. In 2017, Huang et al 60 discovered LBBP during HBP implantation in a patient with heart failure and LBBB. High pacing output failed to correct the LBBB with HBP, and advancing the pacing lead approximately 15 mm toward the ventricular side resulted in successful engagement of the left bundle branch and marked the discovery of LBBP.60 In addition to making His-Purkinje pacing more applicable by reducing the failure rate, LBBP provides more space for AV node ablation and may help to avoid later deterioration at the proximal His bundle or AV node caused by the progression of AV conduction delay.60 Since 2017, we have witnessed an explosion of studies and a global expansion of CSP, supported by large observational studies61–63 and only a few randomised trials, but showing very promising results. Regarding available trials on CRT indication, the LEVEL-AT trial64 showed non-inferiority of CSP (4 patients with HBP, 31 LBBP) compared with BiVP, decreasing left ventricular activation time. LBBP-Resync65 and His-optimised CRT (HOT-CRT)66 trials showed LBBP superiority, increasing LVEF at 6-month follow-up. A secondary analysis of the LEVEL-AT trial demonstrated that CSP and BiVP obtained a comparable correction of dyssynchrony, improvement in LVEF and reduction in LV end-systolic volume at 12-month follow-up.67 The recently published CONSYST-CRT trial68 showed that CSP was non-inferior to BiVP in achieving clinical and echocardiographic response, suggesting that CSP may be an alternative to BiVP (table 2, figure 3A). The CONSYST trial is the only published trial for CRT indication with a clinical endpoint, but it should be noted that this is a combined endpoint. HBP and LBBP are inherently limited in restoring physiological activation in patients with diffuse distal conduction disease (intact Purkinje activation) or intramyocardial disease.56 69 In this context, HOT-CRT or left bundle branch-optimised CRT (LOT-CRT)70 emerged as a potential strategy to provide better results in patients who present with a very wide QRS or obtain suboptimal response with HBP or LBBP. HOT-CRT and LOT-CRT consist of combining an electrode in the His or left bundle position, respectively, with a coronary sinus lead. The CSPOT study,71 in a CRT cohort with advanced conduction disease, found that LOT-CRT and BiVP provided greater acute haemodynamic benefit than LBBAP. Patients who are more likely to benefit from LOT-CRT are those with suboptimal LBBAP, wider QRS or ischaemic cardiomyopathy.71 In addition to CRT trials, three recent trials have provided new insights into patients with AV block. The STAY trial72 randomised 75 patients with a high-degree AV block and preserved or mildly deteriorated LVEF (>40%) to RV apical pacing versus CSP. At 6 months, the RV pacing group showed a greater decline in LVEF (mean difference −5.8%, p<0.01) and a higher rate of heart failure-related admissions compared with the CSP group. In the Prague CSP trial,73 patients with pacemaker indication due to the AV conduction disease and LVEF >45% showed a smaller LVEF decline with CSP compared with RV pacing after 1 year (−2% vs −4%, p=0.03). Finally, the recently published CSPACE74 trial demonstrated the superiority of CSP over RV septal pacing in achieving improved clinical outcomes. His bundle pacing and left bundle branch pacing in the guidelines HBP was referenced in the American guidelines (2018) as a plausible option in patients with AV block and permanent pacing indication with LVEF between 36% and 50%, who were expected to require ventricular pacing more than 40% of the time.75 European guidelines (2021) supported HBP in patients with failed coronary sinus lead implant or in those with AV block and LVEF >40% who were anticipated to have >20% ventricular pacing.76 It was not until 2023 with the Heart Rhythm Society guideline on cardiac physiological pacing for the avoidance and mitigation of heart failure,77 followed in 2025 by the European Society of Cardiology (ESC) clinical consensus statement on indications for CSP 55 that specific recommendations regarding LBBAP have been introduced (table 1B, table 3). It should be noted that the ESC document represents a consensus statement rather than a formal guideline. Whether conduction system capture improves outcomes compared with LV septal pacing is still unknown. Table 3Advice according to the 2025 European Society of Cardiology clinical consensus on indications for CSP55 HBP versus LBBAP HBP LBBAP It is advised that HBP is preferred over LBBAP in patients requiring sparing of the tricuspid valve (eg, after tricuspid valve surgery or transcatheter repair). Bailout in case of unsuccessful/unsatisfactory LBBAP. It is advised that LBBAP is preferred over HBP in patients with the following:Significant aortic valve disease.Previous or scheduled transcatheter aortic valve implantation or aortic valve surgery.Infra-nodal AV block.AV node ablation. Bailout in case of unsuccessful/unsatisfactory HBP CSP implantation centres should ideally be capable of performing both HBP and LBBAP and able to perform BiVP implantation.Advice by indication CSP for AV block CSP for CRT In patients with AV block in whom BiVP is desired, it is advised to implant CSP as a rescue strategy if coronary sinus lead implantation fails.It may be appropriate to implant CSP in patients with LVEF >40% with an anticipated ventricular pacing burden >20%.It may be appropriate to implant CSP in lieu of BiVP in patients with AV block and LVEF <40% with an anticipated ventricular pacing burden >20%.In patients with AV block and infrequent (<20%) anticipated ventricular pacing, it may be appropriate to implant CSP in combination with minimised ventricular pacing strategies. In candidates for BiVP in whom coronary sinus lead implantation is unsuccessful, CSP is advised as rescue therapy.For patients with LVEF ≤35%, LBBB with QRS ≥130 ms and NYHA II–IV heart failure symptoms despite guideline-directed medical therapy, CSP may be appropriate as an alternative to BiVP.In non-responders to BiVP-CRT, it may be appropriate to implant CSP to improve heart failure symptoms and LVEF.In the presence of specific patient populations where a simpler device is desired*, it may be appropriate to choose CSP instead of BiVP as a primary strategy, taking into account operator experience.In patients with pacing-induced cardiomyopathy, it may be appropriate to upgrade to CSP to improve heart failure symptoms and LVEF, particularly in patients with an intact His-Purkinje system. CSP for AV node ablation LOT/HOT-CRT It is advised that CSP be implanted as a rescue strategy if coronary sinus lead implantation fails.It may be appropriate that patients undergoing HBP as a primary strategy for ablate-and-pace therapy receive a backup ventricular lead in the interest of safety.In patients with an LVEF >40% undergoing AV node ablation, it may be appropriate to implant CSP in lieu of RV pacing or BiVP in order to preserve LV function and improve heart failure symptoms.In patients with an LVEF ≤40% undergoing AV node ablation, it may be appropriate to implant CSP in lieu of BiVP in order to improve LV function and heart failure symptoms.In the presence of specific patient populations where a simpler device is desired*, it may be appropriate to choose CSP instead of BiVP as a primary strategy, taking into account operator experience. It may be appropriate to propose HOT/LOT-CRT at implantation in case of suboptimal electrocardiographic results of CSP or BiVP, taking into account operator experience and patient risk.It may be appropriate to propose HOT/LOT-CRT as an upgrade procedure in selected CRT candidates in cases of suboptimal clinical and electrocardiographic results with CSP or BiVP, especially in the setting of non-specific intraventricular conduction delay or mixed conduction disease, taking into account operator experience and patient risk. *Frail patients, patients with limited life expectancy or those requiring a smaller device.AV, atrioventricular; BiVP, biventricular pacing; CRT, cardiac resynchronisation therapy; CSP, conduction system pacing; HBP, His bundle pacing; HOT-CRT, HBP+coronary sinus lead; LBBAP, left bundle branch area pacing; LBBB, left bundle branch block; LOT-CRT, LBBAP+coronary sinus lead; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RV, right ventricle. Advice according to the 2025 European Society of Cardiology clinical consensus on indications for CSP55 Significant aortic valve disease. Significant aortic valve disease. Previous or scheduled transcatheter aortic valve implantation or aortic valve surgery. Previous or scheduled transcatheter aortic valve implantation or aortic valve surgery. Infra-nodal AV block. Infra-nodal AV block. AV node ablation. AV node ablation. In patients with AV block in whom BiVP is desired, it is advised to implant CSP as a rescue strategy if coronary sinus lead implantation fails. In patients with AV block in whom BiVP is desired, it is advised to implant CSP as a rescue strategy if coronary sinus lead implantation fails. It may be appropriate to implant CSP in patients with LVEF >40% with an anticipated ventricular pacing burden >20%. It may be appropriate to implant CSP in patients with LVEF >40% with an anticipated ventricular pacing burden >20%. It may be appropriate to implant CSP in lieu of BiVP in patients with AV block and LVEF <40% with an anticipated ventricular pacing burden >20%. It may be appropriate to implant CSP in lieu of BiVP in patients with AV block and LVEF <40% with an anticipated ventricular pacing burden >20%. In patients with AV block and infrequent (<20%) anticipated ventricular pacing, it may be appropriate to implant CSP in combination with minimised ventricular pacing strategies. In patients with AV block and infrequent (<20%) anticipated ventricular pacing, it may be appropriate to implant CSP in combination with minimised ventricular pacing strategies. In candidates for BiVP in whom coronary sinus lead implantation is unsuccessful, CSP is advised as rescue therapy. In candidates for BiVP in whom coronary sinus lead implantation is unsuccessful, CSP is advised as rescue therapy. For patients with LVEF ≤35%, LBBB with QRS ≥130 ms and NYHA II–IV heart failure symptoms despite guideline-directed medical therapy, CSP may be appropriate as an alternative to BiVP. For patients with LVEF ≤35%, LBBB with QRS ≥130 ms and NYHA II–IV heart failure symptoms despite guideline-directed medical therapy, CSP may be appropriate as an alternative to BiVP. In non-responders to BiVP-CRT, it may be appropriate to implant CSP to improve heart failure symptoms and LVEF. In non-responders to BiVP-CRT, it may be appropriate to implant CSP to improve heart failure symptoms and LVEF. In the presence of specific patient populations where a simpler device is desired*, it may be appropriate to choose CSP instead of BiVP as a primary strategy, taking into account operator experience. In the presence of specific patient populations where a simpler device is desired*, it may be appropriate to choose CSP instead of BiVP as a primary strategy, taking into account operator experience. In patients with pacing-induced cardiomyopathy, it may be appropriate to upgrade to CSP to improve heart failure symptoms and LVEF, particularly in patients with an intact His-Purkinje system. In patients with pacing-induced cardiomyopathy, it may be appropriate to upgrade to CSP to improve heart failure symptoms and LVEF, particularly in patients with an intact His-Purkinje system. It is advised that CSP be implanted as a rescue strategy if coronary sinus lead implantation fails. It is advised that CSP be implanted as a rescue strategy if coronary sinus lead implantation fails. It may be appropriate that patients undergoing HBP as a primary strategy for ablate-and-pace therapy receive a backup ventricular lead in the interest of safety. It may be appropriate that patients undergoing HBP as a primary strategy for ablate-and-pace therapy receive a backup ventricular lead in the interest of safety. In patients with an LVEF >40% undergoing AV node ablation, it may be appropriate to implant CSP in lieu of RV pacing or BiVP in order to preserve LV function and improve heart failure symptoms. In patients with an LVEF >40% undergoing AV node ablation, it may be appropriate to implant CSP in lieu of RV pacing or BiVP in order to preserve LV function and improve heart failure symptoms. In patients with an LVEF ≤40% undergoing AV node ablation, it may be appropriate to implant CSP in lieu of BiVP in order to improve LV function and heart failure symptoms. In patients with an LVEF ≤40% undergoing AV node ablation, it may be appropriate to implant CSP in lieu of BiVP in order to improve LV function and heart failure symptoms. In the presence of specific patient populations where a simpler device is desired*, it may be appropriate to choose CSP instead of BiVP as a primary strategy, taking into account operator experience. In the presence of specific patient populations where a simpler device is desired*, it may be appropriate to choose CSP instead of BiVP as a primary strategy, taking into account operator experience. It may be appropriate to propose HOT/LOT-CRT at implantation in case of suboptimal electrocardiographic results of CSP or BiVP, taking into account operator experience and patient risk. It may be appropriate to propose HOT/LOT-CRT at implantation in case of suboptimal electrocardiographic results of CSP or BiVP, taking into account operator experience and patient risk. It may be appropriate to propose HOT/LOT-CRT as an upgrade procedure in selected CRT candidates in cases of suboptimal clinical and electrocardiographic results with CSP or BiVP, especially in the setting of non-specific intraventricular conduction delay or mixed conduction disease, taking into account operator experience and patient risk. It may be appropriate to propose HOT/LOT-CRT as an upgrade procedure in selected CRT candidates in cases of suboptimal clinical and electrocardiographic results with CSP or BiVP, especially in the setting of non-specific intraventricular conduction delay or mixed conduction disease, taking into account operator experience and patient risk. *Frail patients, patients with limited life expectancy or those requiring a smaller device. AV, atrioventricular; BiVP, biventricular pacing; CRT, cardiac resynchronisation therapy; CSP, conduction system pacing; HBP, His bundle pacing; HOT-CRT, HBP+coronary sinus lead; LBBAP, left bundle branch area pacing; LBBB, left bundle branch block; LOT-CRT, LBBAP+coronary sinus lead; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RV, right ventricle. Leadless pacing Current technical developments aim to achieve leadless CSP78 and to reduce the lead burden.79 Leadless pacing reached its first milestone in 2025 with the publication of a first-in-human acute feasibility study evaluating the safety and performance of a novel helix-based LP for LBBAP in 10 patients78. The study demonstrated successful acute implantation of the device with clinically acceptable intraprocedural electrical performance and safety. Defibrillation from a LBBAP lead The delivery of defibrillation through the same lead used for LBBAP represents a novel, unresolved challenge that is currently under investigation. If a single lead cannot both pace and defibrillate, an additional lead is required, with the associated procedural risks and potential complications. The Lead Evaluation for Defibrillation and Reliability in LBBAP (NCT04863664) study is currently underway. It was designed to confirm the safety and defibrillation efficacy of a novel, lumenless, small-diameter defibrillation lead80 (OmniaSecure, Medtronic) when placed in the LBBAP location in ICD and LOT-CRT patient population. To date, only 3-month results have been reported.81 This is an elegant and simple approach that uses a single lead to provide both defibrillation and physiological pacing.79 82 Knowledge gaps in conduction system pacing We are entering a new era of cardiac pacing; however, we are still in the early stages of implementing new technologies. No randomised studies are currently available for LOT-CRT or HOT-CRT. Leadless LBBAP pacing has only just begun to emerge. The largest randomised trials investigating CSP for CRT barely exceed 100 patients each, with follow-up periods of 1 year or less. These CSP studies have been conducted in high-volume centres with extensive expertise; whether widespread implementation of LBBAP in less experienced centres will yield similar results remains unknown. The proliferation of novel technologies generates enthusiasm, but that should not overshadow the limited clinical experience supporting them. High-quality randomised controlled trials are crucial to rigorously evaluate their safety, efficacy and long-term outcomes prior to widespread clinical adoption. Large ongoing randomised trials such as Left vs Left (NCT05650658) and PROTECT-HF (NCT05815745), when results become available, may help address the remaining unanswered questions regarding the clinical benefits of CSP. Much of the current effort is directed towards demonstrating the potential benefits of CSP, as physiological pacing should, in theory, always be more effective at resynchronising than pacing the myocardium via cell-to-cell conduction (figure 3B). However, in clinical practice, we deal with patients with diverse characteristics (different types of blocks, intact Purkinje activation, extensive scarring, septal infarctions, etc). In the era of precision medicine, rather than replacing BiVP with CSP for all patients, it would be preferable to apply evidence-based criteria to select the most appropriate therapy for each individual. Conclusion The latest technological developments in the field of cardiac pacing and defibrillation may allow us to adapt to the specific needs of each patient, depending on their underlying pathology, baseline characteristics and risk of arrhythmic events. Therapy personalisation is still in its early stages, both in terms of pacing modality and the need for ICD therapy according to scar burden. We are still far from being able to anticipate the optimal treatment for each patient. Nonetheless, we are progressively moving closer, and randomised clinical trials will help bridge the gap. The greatest obstacle to discovery is the illusion of knowledge. Daniel J Boorstin Acknowledgments The authors thank the CERCA Program/Generalitat de Catalunya for support to Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). The authors would like to thank Laia Garrit Nicolau and Aitor Toledo Silva (Boston Scientific) for their collaboration. Footnotes Contributors: All authors contributed significantly to the development and completion of this review. MP-L: Conception and design of the review; drafting and writing the review; final approval of the manuscript. RT: Critical revision of the manuscript; final approval of the manuscript. LM (guarantor): Conception and design of the review; critical revision of the manuscript; final approval of the manuscript. Funding: LM was funded by a 2021 Support for Research Groups grant from the Catalan government (2021_SGR_01350, SGR21/GENCAT), Catalonia, Spain. Competing interests: MP-L has received speaker honouraria from Medtronic and Abbott. Dr RT has received speaking fees and advisory board fees from Abbott, Biotronik, Boston Scientific and Medtronic; and research grant support from Abbott. Dr LM has received research grants, support for his centre’s fellowship programme and honouraria as a lecturer and consultant from Abbott, Biotronik, Boston Scientific and Medtronic; he holds stock in Galgo Medical SL and Corify Care SL. Provenance and peer review: Commissioned; externally peer reviewed. Supplemental material: This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. Ethics statements Patient consent for publication Not applicable. Ethics approval Not applicable. References Associated Data Supplementary Materials heartjnl-112-17-s001.pdf